ScreenerHero

CMMBChemomab Therapeutics Ltd.

NAS · US · Healthcare · Biotechnology · chemomab.com
2.160USDMkt Cap: 15.83M $P/E: —

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap15.83M $
Enterprise Value8.96M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.99M $
Revenue/Share—
Last Price2.160 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS16385C1045
Valuation
P/E (Trailing)—
P/E (Forward)-72.00
PEG—
EV/EBITDA-1.14
EV/Revenue—
P/S—
P/B1.80
EPS (TTM)-0.96
EPS (Forward)-0.03
52W Range
2.05073% of range2.200
52W High2.200 USD
52W Low2.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.93%
ROA-65.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.13M $
CapEx (TTM)3.00K $
FCF Margin—
FCF Yield—
Net Debt-6.69M $
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.00
Current Ratio6.41
Quick Ratio6.41
Book Value/Sh1.199 USD
Cash/Share0.9230 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateAug 26, 2025
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.000 USD
Upside (mean)+131.5%
Target Range5.000 USD – 5.000 USD
# Analysts1
Ownership
Shares Out.7.33M
Float6.06M
Insiders7.06%
Institutions8.29%
Short Interest
Short Ratio0.6d
Short % Float2.18%
Short % Out.2.12%
Shares Short155.60K
Short (prev mo.)143.14K
Technical
SMA 501.722 (+25.5%)
SMA 2001.842 (+17.2%)
Beta0.66
S&P 52W Chg19.18%
Avg Vol (30d)106.95K
Avg Vol (10d)49.86K
Technical Indicators
RSI (14)71.1
MACD0.1140
MACD Signal0.0742
MACD Hist.+0.0398
BB Upper2.243 USD
BB Middle1.792 USD
BB Lower1.341 USD
BB Width50.30%
ATR (14)0.1384 USD
Vol Ratio (20d)1.72x